Geron Corporation (GERN)
Symbol Info
Listed Symbol GERN
Name Geron Corporation
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $1,066,000
Latest Fiscal EPS $-0.15
Price Info
21 Day Moving Average $1.4329
21 Day EMA $1.429150
50 Day Moving Average $1.3916
50 Day EMA $1.409950
200 Day EMA $1.619410
200 Day Moving Average 1.444200
52 Week High $2.14
52 Week Low $0.95
52 Week Change $-7.831300
Alpha 0.005109
Beta 2.4650
Standard Deviation 0.238831
R2 0.125756
Periods 60
Share Information
10 Day Average Volume 1,780,873
20 Day Average Volume 1,452,523
30 Day Average Volume 1,509,029
50 Day Average Volume 1,406,391
Outstanding Shares 188,423,106
Float Shares 183,516,849
Percent Float 97.40%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 245
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 2,782,498
Institute Holdings Percent 54.600000
Institute Sold Previous 3 Months 12,141,764
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 6
Insider Holdings Percent 2.60%
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,906,257
Price Change
7 Day Price Change $0.1000000
7 Day Percent Change 6.99%
21 Day Price Change $0.1000000
21 Day Percent Change 6.99%
30 Day Price Change $0.0400000
30 Day Percent Change 2.68%
Month To Date Price Change $0.2000
Month To Date Percent 15.04%
90 Day Price Change $0.220000
90 Day Percent Change 16.79%
Quarter To Date $0.200000
Quarter To Date Percent 15.04%
180 Day Price Change $-0.49
180 Day Percent Change -24.26%
200 Day Price Change $-0.11
200 Day Percent Change -6.71%
Year To Date $0.530000
Year To Date Percent 53.00%
Profile
Description Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.
Details
Issue Type CS
Market Cap $288,287,352
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 188,423,106
CEO John A. Scarlett
Employees 18
Last Audit UE
Classification
CIK 0000886744
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
Website https://www.geron.com
Facisimile +1 650 473-7750
Telephone +1 650 473-7700
Email investor@geron.com
Key Ratios
Profitability
EBIT Margin -6,148.9
EBITDA Margin -6,141.1
Pre-Tax Profit Margin -1,745.7
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $533,000
Revenue Per Share $0.0028
Revenue 3 Years $-50.53
Revenue 5 Years $-22.75
Valuation Measures
PE Ratio -
Enterprise Value $98,516,730
Price To Sales 540.876830
Price To Free Cash -11.2
PE High Last 5 Years -
Price To Book 1.8
Price To Cash Flow 41.1
PE Low Last 5 Years -
Price To Tangible Book 1.8
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 16.9
Leverage Ratio 1.1
Quick Ratio 16.7
Long Term Debt To Capital -
Assets
Receivables Turnover 0.3
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -21.29
Return On Equity -22.18
Return On Capital -24.78
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
GERN
Geron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.